Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR33532759

— · E

cf4e3285-77f9-5edf-8fbf-0a6b02671c83

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.620
  • E2F_TARGETS+0.560
  • G2M_CHECKPOINT+0.490
  • MYC_TARGETS_V2+0.490
  • OXIDATIVE_PHOSPHORYLATION+0.430
  • MTORC1_SIGNALING+0.410
  • PROTEIN_SECRETION+0.330
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
  • UNFOLDED_PROTEIN_RESPONSE+0.210
  • UV_RESPONSE_UP+0.200

Top 10 suppressed

  • ANGIOGENESIS-0.390
  • COAGULATION-0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
  • P53_PATHWAY-0.270
  • NOTCH_SIGNALING-0.260
  • APICAL_JUNCTION-0.250
  • INTERFERON_ALPHA_RESPONSE-0.250
  • MYOGENESIS-0.230
  • IL2_STAT5_SIGNALING-0.220
  • KRAS_SIGNALING_UP-0.220

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
157ab4aef-e740-4494-b0b5-3b008f9d446f
melanoma-umap@29
——0.907
2SRR23303750
bladder-landscape@3
——0.904
3TCGA-66-2787-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.890
4SRR35579804
breast-umap@18
—C0.884
51c3eaf9a-ffda-4c6d-bffb-2610a37ab837
melanoma-umap@29
——0.878
6SRR8613799
breast-umap@18
—E0.878
7TCGA-AN-A0AK-01A-21R-A00Z-07
breast-umap@18
—C0.878
8SRR1313140
breast-umap@18
—E0.875
9MBCProject_4634_T1_RNA
breast-umap@18
—E0.873
1045a758dc-af09-48d3-8cd2-15232593f385
colon-landscapes@1
——0.873

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.620Inavolisib— uncovered
E2F_TARGETS0.560Inavolisib— uncovered
G2M_CHECKPOINT0.490Inavolisib— uncovered
MYC_TARGETS_V20.490Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.430Remibrutinib— uncovered
MTORC1_SIGNALING0.410Inavolisib— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.210Idelalisib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
SPERMATOGENESIS0.190Inavolisib— uncovered
GLYCOLYSIS0.170Inavolisib— uncovered
ANDROGEN_RESPONSE0.160Inavolisib— uncovered
FATTY_ACID_METABOLISM0.160Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
MITOTIC_SPINDLE0.080Inavolisib— uncovered
ADIPOGENESIS0.070Inavolisib— uncovered
HEME_METABOLISM0.050Temsirolimus— uncovered
PI3K_AKT_MTOR_SIGNALING0.040Inavolisib— uncovered